Xbrane Biopharma (XBRANE) Q4 2026 earnings summary

Executive summary

• Lucamzi received FDA approval on October 29, 2026; US launch is planned for 2027 through Valorum Biologics, with STADA handling regulatory completion and Xbrane responsible for manufacturing and supply.

• Ximluci is commercial in 24 Europe and MENA countries; Xdivane’s pivotal PK trial is fully recruited, while Xdarzane process development is underway with JOINN.

• The presentation targets a path to full-year profitability, supported by product shipments, profit sharing, cost reduction efforts and a stabilized balance sheet.

Financial highlights

• 2026Q3 YTD revenue SEK 118.9m, gross profit SEK 18.2m and operating loss SEK 28.8m; revenue included SEK 89.2m in product sales to STADA and SEK 29.2m in profit sharing.

• FY2025 revenue was SEK 152.4m, gross profit SEK 89.6m and operating loss SEK 28.2m; FY2024 revenue was SEK 198.7m and operating profit SEK 180.5m.

• Ximluci-related inventory, including finished goods, was valued at SEK 149m at Q3 2026 and expected to convert to cash during 2026–2027 as deliveries to STADA resume.

Outlook and guidance

• Lucamzi launch with a Q code is planned for Q3 2027; Q-code application and launch-material production were scheduled for Q4 2026.

• Ximluci production cost reduction measures are expected to affect costs in 2027–2028; the presentation also cites ongoing cost reductions for 2027 onward.

• Xdivane interim pivotal PK trial readout is expected in Q2 2027; BLA submission is planned ahead of a targeted US launch at Opdivo’s December 2028 patent expiry.

• Xdarzane is intended for out-licensing to a commercialization partner that would fund most remaining development; no investment requirements were stated for the current JOINN process-development stage.